Rheumatology News

Olokizumab combined with methotrexate for the treatment of rheumatoid arthritis maintains its safety and efficacy profile through 106 weeks, according to data published in Annals of the Rheumatic Diseases.

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

In his keynote address at this year’s Ending Clinician Burnout Global Summit, Thom Mayer, MD, FACEP, likened the health care practitioners in the audience to the professional football players he routinely treats.

ORLANDO, Fla. — Evidence-based medical practices can be fostered through a five-step process that begins with asking the right questions, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

Cell-free DNA analyses were accurate in detecting fetal antigen status as early as 10 weeks’ gestation in women with alloimmunized pregnancies, according to results of a large, diverse U.S. cohort study published in Obstetrics & Gynecology.

As medical technology quickly evolves, practices in nearly all areas of medicine must frequently evaluate equipment upgrades and new purchases of new technology to stay at the forefront of patient care.

ORLANDO, Fla. — Although rheumatic diseases must be considered in a differential diagnosis of autoimmune encephalitis, some patients can have both, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

Most clinicians expressed positive attitudes and increased knowledge about climate change and health following the completion of a quality incentive program, researchers found.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.